Chardan Capital Maintains Buy on Immuneering, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Immuneering (NASDAQ:IMRX) but lowers the price target from $16 to $12.
August 07, 2024 | 11:57 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chardan Capital maintains a Buy rating on Immuneering but lowers the price target from $16 to $12.
The Buy rating suggests continued confidence in Immuneering's prospects, but the lowered price target indicates tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100